Retatrutide in Type 2 Diabetes: What the First Phase 3 Diabetes Trial TRANSCEND-T2D-1 Shows (Lancet, June 2026)
TRANSCEND-T2D-1 is the first Phase 3 trial of Retatrutide in type 2 diabetes. HbA1c down to -2.0 points and up to 15.3% weight loss as monotherapy. The numbers in research context.
Important note: This article is provided exclusively for scientific information and research purposes. Retatrutide is a research peptide, not intended for human consumption and not approved as a medicine anywhere. No therapeutic recommendations or dosing instructions are given.
TL;DR: TRANSCEND-T2D-1 in one paragraph
Date: Topline reported in March 2026, full data presented at the ADA Scientific Sessions in June 2026 and published in The Lancet. What it is: The first Phase 3 trial to study Retatrutide specifically in type 2 diabetes, not in obesity. Key finding: 537 adults, 40 weeks, Retatrutide as monotherapy. HbA1c fell by roughly 1.7 to 2.0 points depending on dose (versus -0.8 on placebo), and weight loss came in at roughly 11.5 to 15.3% (versus -2.6%). Relevance: This is the diabetes trial, not the TRIUMPH obesity trials. Retatrutide remains an unapproved investigational peptide.
First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.
Why this trial is its own headline
Retatrutide is Eli Lilly's triple agonist: a single molecule that activates the receptors for GLP-1, GIP and glucagon at the same time. Across 2026 the peptide delivered a whole series of Phase 3 readouts, and this is exactly where confusion keeps arising. Most of the attention went to the TRIUMPH program, which studies the compound in obesity. TRANSCEND-T2D-1 is a different trial with a different population and a different question.
The question here is not "How much weight does a person with obesity lose?" but "How does Retatrutide behave in people with type 2 diabetes, specifically without any other glucose-lowering medication?". That makes TRANSCEND-T2D-1 the first clean monotherapy readout of the triple agonist in the diabetes indication.
Trial design in brief
Phase 3, randomized, double-blind, placebo-controlled. 537 adults with type 2 diabetes were assigned in a 1:1:1:1 ratio to three Retatrutide doses (4 mg, 9 mg, 12 mg, once weekly subcutaneously) and placebo. Trial duration 40 weeks. Retatrutide was tested as monotherapy, meaning without any additional antidiabetic agents. Primary endpoint: change in HbA1c. Baseline HbA1c in the range of roughly 7.0 to 9.5%.
The core numbers
Two axes are of interest: glycemic control (HbA1c) and weight loss. Both showed a clear dose-response relationship.
- HbA1c reduction (40 weeks)
- about 1.7 to 2.0 points
- Weight loss
- about 11.5 to 15.3%
- HbA1c reduction (40 weeks)
- about 0.8 points
- Weight loss
- about 2.6%
As the dose increased, both the HbA1c reduction and the weight loss grew. The highest dose (12 mg) delivered the strongest glycemic control along with the largest weight loss. This is notable because it was a monotherapy: these HbA1c reductions were achieved without any additional diabetes medication.
Putting the weight numbers in context
For weight, trials like this can report two estimators: the effect under ideal use (efficacy estimand) and the effect across the whole assigned group including dropouts (treatment-regimen estimand). The figures here are the treatment-regimen estimand, the more conservative of the two, up to about 15.3% at the 12 mg dose. We cite that intention-to-treat number throughout.
TRANSCEND is not TRIUMPH
So that the data are read correctly, here is the distinction from the trials we have already described elsewhere:
- TRANSCEND-T2D-1 (this trial): type 2 diabetes, monotherapy, 40 weeks, focus on HbA1c and weight.
- TRIUMPH-1: broad obesity population without diabetes, up to 28.3% weight loss after 80 weeks. Details in the article Retatrutide TRIUMPH-1.
- TRIUMPH-4: obesity with knee osteoarthritis. Details in the article Retatrutide TRIUMPH-4.
Anyone comparing the numbers should keep the difference in mind: in the diabetes population the percentage weight losses are naturally lower than in a pure obesity population without diabetes. This is a well-known pattern across the entire incretin class and not a sign of weakness in the trial.
Why a triple agonist is interesting in the diabetes question
GLP-1 and GIP act mainly on appetite, satiety and insulin signaling. The glucagon arm, which distinguishes Retatrutide from pure GLP-1 or dual agonists, additionally increases energy expenditure. In diabetes research, glucagon agonism was long a point of contention, because glucagon on its own tends to raise blood glucose. That TRANSCEND-T2D-1 shows a clear HbA1c reduction as monotherapy despite the glucagon component is exactly the mechanistically interesting part: the GLP-1- and GIP-mediated effects plus the weight loss overcompensate for the potentially glucose-raising glucagon effect.
Mechanism, briefly
Three receptors, one molecule. GLP-1 and GIP improve insulin secretion and satiety, glucagon increases energy expenditure. The net effect in TRANSCEND-T2D-1: less HbA1c and less weight, as monotherapy. The full breakdown by receptor contribution is the subject of ongoing research.
Tolerability
Mainly gastrointestinal
As with the entire incretin class, the most common side effects were gastrointestinal: nausea, diarrhea, constipation. They were predominantly mild to moderate and dose-dependent, meaning they occurred more frequently in the higher dose arms. The full safety profile including rarer signals will only emerge from the peer-reviewed full-text publication.
For research, the dose-tolerability relationship is the part that actually matters: it explains why a stepwise titration and professional supervision are central in clinical development. The strongest effect (12 mg) is also the one with the highest side-effect burden.
What this means for the EU research context
Read the data, do not confuse it with approval
TRANSCEND-T2D-1 is a strong trial, but it changes nothing about the regulatory status: Retatrutide is not approved as a medicine in either the EU or the US. Eli Lilly has not yet filed a marketing application (NDA). Anyone obtaining the peptide is obtaining a research material, not a medicine. That is precisely why identity and purity are the decisive questions, not the package insert that does not exist.
With an unapproved investigational peptide there is no officially controlled production. That makes the independent analysis of every batch the actual quality marker. Our Retatrutide batches are tested at Janoshik for identity and purity, the certificate is viewable per batch and verifiable via the verify function.
First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.
USP-grade sterile water with 0.9% benzyl alcohol (near-neutral, ~pH 5.7) - the standard solvent for reconstituting lyophilized peptides. Essential accessory for any peptide research. Each vial is sealed and ready to use.
Further reading
- Buying Retatrutide: research overview and purity
- Retatrutide vs Tirzepatide vs Semaglutide
- Retatrutide dosing and titration in the research protocol
- Retatrutide side effects and safety profile
- GLP-1, GIP and glucagon: the triple agonist explained
FAQ
Sources
-
TRANSCEND-T2D-1, full text. The Lancet, 2026. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00967-0/abstract
-
Eli Lilly and Company. Topline announcement on Retatrutide in type 2 diabetes, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-demonstrated-significant
-
TCTMD. "Positive Top-Line Results for Retatrutide in Diabetes (TRANSCEND-T2D-1)." https://www.tctmd.com/news/positive-top-line-results-retatrutide-diabetes-transcend-t2d-1
-
SpringerMedicine, ADA 2026 coverage of TRANSCEND-T2D-1. https://www.springermedicine.com/type-2-diabetes/ada-2026/transcend-t2d-1-retatrutide-effective-type-2-diabetes-treatment/52527818
Research disclaimer: All content is provided exclusively for scientific information. Retatrutide is not intended for human consumption and not approved as a medicine. The figures mentioned come from trial reports and are not a substitute for medical advice.
Research context for English-speaking buyers
Most of our English-speaking customers ship to the UK, Ireland, Malta or other English-as-second-language EU territories. The regulatory picture differs per country.
- Relevant authorities
- MHRA (UK, post-Brexit), HPRA (Ireland, EU-aligned), FDA Section 503A bulks list (US, restricted Cat 2 status of several peptides as of 2026)
- Customs and VAT
- EU shipments include 19% VAT; UK shipments after Brexit are now extra-EU and may attract UK VAT plus a handling fee at import
- Typical shipping window
- EU 2-4 working days, UK 4-7 working days, other international 7-14 working days, depending on customs
Research-grade peptides shipped from our EU warehouse are sold for laboratory use only and are not authorised for human or veterinary therapeutic application in any of the destination jurisdictions. US customers should be aware that the FDA Section 503A bulks list classification (and the April 2026 reclassification of twelve compounds) only governs compounding pharmacies, not direct-to-researcher imports for non-clinical work. UK buyers should declare the consignment on import and may be asked for a research justification by HMRC. We provide a CoA per batch identified by colour code rather than serial number; customs sometimes asks for this document when clearing the parcel.